POLD4 Gene Expression as a Prognostic Indicator for Synthetic Lethality with PARP Inhibitors in Lung Cancer Cells
Abstract
These studies are directed toward studies of p12, a protein that is a component of a key enzyme that is involved in synthesis of DNA during replication and also when DNA is repaired. It has been found that non-small lung cancer cells have very low levels of p12. Our studies are based on the concept that cells lacking p12 will be deficient in DNA repair, and therefore more sensitive to PARP inhibitors, which have been useful drugs in cancers where DNA repair is compromised. We will perform experiments to establish the principle in cells where we have knocked out the gene for p12. Our first goal is to determine whether indeed these cells are more sensitive to PARP inhibitors. Our second goal will be to analyze the levels of p12 in a selected number of small cell lung cancer cell lines. We will then determine whether those cell lines that are deficient in p12 exhibit higher sensitivity toward PARP inhibitors. These studies could lead to the use of p12 as a marker to determine whether PARP inhibitors will be effective for different types of cancer.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 29, 2018
- Source ID
- W81XWH1810353
Entities
People
- Sufang Zhang
Organizations
- New York Medical College
- United States Army